Mostrar el registro sencillo del ítem
resumen
Resumen
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast
[ver mas...]
dc.contributor.author | Chiavenna, Sebastián Matias | |
dc.contributor.author | Jaworski, Juan Pablo | |
dc.contributor.author | Vendrell, Alejandrina | |
dc.date.accessioned | 2017-07-03T15:04:59Z | |
dc.date.available | 2017-07-03T15:04:59Z | |
dc.date.issued | 2017-02-20 | |
dc.identifier.issn | 1423-0127 | |
dc.identifier.other | https://doi.org/10.1186/s12929-016-0311-y | |
dc.identifier.uri | http://hdl.handle.net/20.500.12123/548 | |
dc.identifier.uri | https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y | |
dc.description.abstract | Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice. | |
dc.format | application/pdf | |
dc.language.iso | eng | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.source | Journal of biomedical science (2017) : 24:15 | |
dc.subject | Neoplasmas | |
dc.subject | Neoplasms | eng |
dc.subject | Anticuerpos Monoclonales | |
dc.subject | Monoclonal Antibodies | eng |
dc.subject | Inmunoterapia | |
dc.subject | Immunotherapy | eng |
dc.subject.other | Cáncer (Enfermedad) | |
dc.title | State of the art in anti-cancer mAbs | |
dc.type | info:ar-repo/semantics/artículo | |
dc.type | info:eu-repo/semantics/publishedVersion | eng |
dc.type | info:eu-repo/semantics/article | eng |
dc.rights.license | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) | |
dc.description.origen | Instituto de Virología | |
dc.gic | 154038 | |
dc.description.fil | Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España | |
dc.description.fil | Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina | |
dc.description.fil | Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina | |
dc.subtype | cientifico |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
common
-
Artículos científicos [199]